Greg Mullen, PhD, FRSC

Chief Operating Officer at Ariceum Therapeutics

Greg Mullen, PhD, FRSC has a diverse and extensive work experience in the field of biotechnology and medical imaging. Starting in 1998, they worked as a Post Doctoral Scientist at the University of Oxford. From 2001 to 2007, they held various roles at the National Institutes of Health, including being the Head of Vaccine Formulation and Project Manager, as well as a Research Fellow focusing on Innate Immunology Research. Greg then joined King's College London in 2007 as a Senior Lecturer in Imaging Biology, where their research centered around the development of diagnostic biomarkers and investigating the mechanism of action of vaccines using non-invasive imaging techniques.

In 2012, Greg became the R&D Director at Oxford Immunotec and provided strategic input in the company's research and development activities. Greg then served as the Chief Scientific Officer for Molecular Imaging at Mediso Medical Imaging Systems from 2013 to 2015, where they provided scientific and translational advice in preclinical and molecular imaging applications.

In 2015, Greg joined Theragnostics as the Chief Executive Officer, overseeing radiopharmaceutical drug development from non-clinical to clinical trials. In 2023, they became the Chief Operating Officer at Ariceum Therapeutics.

Throughout their career, Greg has demonstrated leadership skills, project management expertise, and a strong focus on regulatory development, toxicology, PK, CMC, and clinical trial design. Greg is recognized as a proactive and result-oriented leader with critical thinking abilities. As a prolific researcher, they have published extensively in their field and holds the prestigious FRSC designation.

Greg Mullen, PhD, FRSC began their educational journey in 1991 at the University of Kent. Greg pursued a Bachelor of Science degree in Chemistry with a specialization in a year at ETH, Switzerland. After completing their undergraduate studies in 1995, they continued their academic pursuits at the University of Kent and achieved a Ph.D. in Chemistry in 1998.

Links

Previous companies

National Institutes of Health logo
Oxford Immunotec logo

Timeline

  • Chief Operating Officer

    June, 2023 - present